id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0249-0008,FDA,FDA-2022-E-0249,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-13T05:00:00Z,2025,1,2025-01-13T05:00:00Z,,2025-01-13T20:15:22Z,,0,0,09000064868b7e67
FDA-2022-E-0249-0007,FDA,FDA-2022-E-0249,Letter from U. S. Patent and Trademark Office,Other,Letter(s),2024-03-06T05:00:00Z,2024,3,2024-03-06T05:00:00Z,,2024-03-06T18:43:15Z,,0,0,09000064863ef707
FDA-2022-E-0249-0006,FDA,FDA-2022-E-0249,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-01-18T05:00:00Z,2024,1,2024-01-18T05:00:00Z,,2024-01-18T21:30:19Z,,0,0,09000064863a950d
FDA-2022-E-0249-0005,FDA,FDA-2022-E-0249,Determination of Regulatory Review Period for Purposes of Patent Extension; Pemazyre,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:50:24Z,2023-26996,0,0,0900006486317518
FDA-2022-E-0249-0004,FDA,FDA-2022-E-0249,Letter to U S Patent and Trademark Office,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T16:38:49Z,,0,0,09000064852ce798
FDA-2022-E-0249-0002,FDA,FDA-2022-E-0249,Patent Extension Application from Fish & Richardson P.C. (on behalf of Incyte Corporation),Other,Application,2022-02-28T05:00:00Z,2022,2,2022-02-28T05:00:00Z,,2022-02-28T21:13:19Z,,0,0,0900006484fae04b
FDA-2022-E-0249-0001,FDA,FDA-2022-E-0249,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-02-28T05:00:00Z,2022,2,2022-02-28T05:00:00Z,,2022-02-28T21:13:14Z,,0,0,0900006484fae049
FDA-2022-E-0249-0003,FDA,FDA-2022-E-0249,Appendix A-H RE Patent Extension Application from Fish & Richardson P.C. (on behalf of Incyte Corporation),Supporting & Related Material,Background Material,2022-02-28T05:00:00Z,2022,2,,,2022-02-28T21:13:24Z,,0,0,0900006484fae6fb